| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Isotope-labeled ceramide-1-phosphate; no intrinsic receptor or enzyme agonist/antagonist activity. Endogenous C1P is a bioactive sphingolipid that regulates cell proliferation, survival, and inflammatory signaling through interactions with cPLA2 and other effector proteins. The deuterated standard is used as an analytical surrogate for C1P quantification and does not modulate ceramide kinase activity or C1P-mediated signaling.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a cause for concern [2].
The d7-C1P standard shows no measurable intrinsic bioactivity and is not used for potency screening. Endogenous C15 C1P is a low-abundance sphingolipid that requires a structurally matched internal standard for accurate quantification; the d7 form co-elutes with the analyte and corrects for extraction recovery, ionization efficiency, and matrix effects during C1P analysis. |
| ln Vivo |
No intrinsic in vivo pharmacological activity has been reported for the deuterated standard. Endogenous C1P regulates cell proliferation, survival, and inflammatory responses in vivo; the d7 standard supports in vivo quantification of C1P species in plasma and tissue and enables studies of ceramide kinase activity and C1P-mediated signaling in animal models.
|
| Enzyme Assay |
LC-MS/MS C1P quantification: add C15 Ceramide-1-phosphate-d7 to the sample before lipid extraction; extract sphingolipids with acidified organic solvent; separate on a reversed-phase C18 column or a HILIC column; monitor the specific m/z transition of the d7 standard (e.g., [M–H]– for the C1P anion) and the corresponding unlabeled C1P transition. Quantification is by isotope-dilution calibration using peak-area ratios.
|
| Cell Assay |
Cell-based C1P profiling: culture cells under conditions that modulate ceramide kinase activity or inflammatory signaling, harvest and quench metabolism, add the d7-C1P internal standard, extract sphingolipids, and analyze by LC-MS/MS.
|
| Animal Protocol |
In vivo tissue C1P analysis: collect plasma or tissue at defined time points, add C15 Ceramide-1-phosphate-d7 before homogenization, extract sphingolipids, and quantify C1P species by LC-MS/MS to assess ceramide kinase activity and C1P-mediated signaling in animal models.
|
| References |
| Molecular Formula |
C33H62D7N2O6P
|
|---|---|
| Molecular Weight |
627.93
|
| Exact Mass |
627.533
|
| CAS # |
2315262-27-0
|
| PubChem CID |
164516964
|
| Appearance |
White to off-white solid
|
| tPSA |
120
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
31
|
| Heavy Atom Count |
42
|
| Complexity |
651
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
[2H]C([2H])([2H])C([2H])([2H])C([2H])([2H])CCCCCCCCCC/C=C/[C@H]([C@H](COP(=O)(O)[O-])NC(=O)CCCCCCCCCCCCCC)O.[NH4+]
|
| InChi Key |
GXIXNMIIJBAQTF-QHKXSBLVSA-N
|
| InChi Code |
InChI=1S/C33H66NO6P.H3N/c1-3-5-7-9-11-13-15-17-18-20-22-24-26-28-32(35)31(30-40-41(37,38)39)34-33(36)29-27-25-23-21-19-16-14-12-10-8-6-4-2;/h26,28,31-32,35H,3-25,27,29-30H2,1-2H3,(H,34,36)(H2,37,38,39);1H3/b28-26+;/t31-,32+;/m0./s1/i1D3,3D2,5D2;
|
| Chemical Name |
azanium;[(E,2S,3R)-16,16,17,17,18,18,18-heptadeuterio-3-hydroxy-2-(pentadecanoylamino)octadec-4-enyl] hydrogen phosphate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5925 mL | 7.9627 mL | 15.9253 mL | |
| 5 mM | 0.3185 mL | 1.5925 mL | 3.1851 mL | |
| 10 mM | 0.1593 mL | 0.7963 mL | 1.5925 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.